W
bioLLM/wiki

AI-Curated Biomedical Knowledge Base

Live
Back to List ViewGraph View

Hepatocyte Nuclear Factor 1 Alpha (HNF1A)

Overview

HNF1A (hepatocyte nuclear factor 1 alpha) is a transcription factor of major biomedical importance, best known for its role in regulating gene expression in metabolic tissues and for its association with monogenic diabetes, particularly HNF1A-MODY (maturity-onset diabetes of the young). As a protein target, HNF1A is clinically relevant because variation in its function can alter pancreatic beta-cell and hepatic transcriptional programs, contributing to inherited dysglycemia and informing diagnostic classification of diabetes subtypes.

In the recent literature provided here, HNF1A appears primarily in the context of diabetes risk assessment rather than as a direct mechanistic focus in immunology. One study specifically addressed the development of a calculator for estimating the probability of HNF1A-MODY in Asian Indians using clinical and biochemical criteria. This underscores HNF1A’s continuing significance as a diagnostic and stratification marker in precision medicine for diabetes.

Recent Publications Summary

Recent publications on HNF1A focused primarily on monogenic diabetes and on HNF1A as a molecular target for precision genome editing. In patient-derived hiPSCs carrying a heterozygous HNF1A frameshift mutation (c.235_236insG; p.Glu79Glyfs*16), investigators developed an optimized CRISPR/Cas9 repair strategy using electroporation delivery of a Cas9-sgRNA ribonucleoprotein complex together with a single-stranded oligodeoxynucleotide repair template. The corrected hiPSC lines were reported to retain pluripotency, lack exogenous reprogramming factors, and show no detectable off-target effects, highlighting a patient-specific platform for correcting HNF1A mutations in HNF1A-MODY 42584708Aug.

Another publication addressed clinical identification of HNF1A-MODY in Asian Indians by developing a calculator to estimate the probability of HNF1A-MODY or HNF4A-MODY using clinical and biochemical criteria 41871534Mar. This work underscores the continued diagnostic relevance of HNF1A in maturity-onset diabetes of the young and reflects efforts to improve targeted recognition of individuals most likely to carry pathogenic HNF1A variants.

What Changes, What Holds

1. HNF1A can now be repaired in patient-derived cells without obvious loss of stem-cell quality
METHOD Patient-specific correction of an HNF1A frameshift in hiPSCs adds a practical disease-modeling and gene-editing platform to the HNF1A-MODY literature, but it does not change the established biologic role of HNF1A in metabolic tissue transcription or its diagnostic significance in monogenic diabetes. The main advance is methodological: a way to study and potentially correct pathogenic HNF1A variants while preserving pluripotency and minimizing off-target concerns 42584708Aug.

2. Probability calculators can sharpen, but do not replace, clinical recognition of HNF1A-MODY
REINFORCES A calculator-based approach for estimating HNF1A-MODY probability extends the baseline diagnostic theme by improving targeted case-finding in Asian Indians, rather than introducing a new role for HNF1A. It strengthens the view that HNF1A remains clinically important for diabetes subtype classification and risk stratification, while leaving unresolved the usual limitation that such tools support but cannot by themselves establish carrier status or functional pathogenicity 41871534Mar.

Overview update candidates: gene-editing correction of pathogenic HNF1A variants in patient-derived hiPSCs; calculator-based refinement of HNF1A-MODY case identification in Asian Indians.

⚠️ Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.